Clinical Trial Update: Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immune response of an investigational mRNA vaccine designed to prevent Respiratory Syncytial Virus infection and Human metap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Metapneumovirus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Investigational mRNA vaccine for Respiratory Syncytial Virus and Human Metapneumovirus (mRNA vaccine targeting Respiratory Syncytial Virus and Human Metapneumovirus)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Respiratory Syncytial Virus Infection, Healthy Volunteers | Phase 1 | Status: COMPLETED